Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation (NCT01714310), a randomized phase 2 study. The primary outcome is Clinical Global Impression-Severity-Severe Mood Dysregulation.

2. Clinical Question

The project also aimed to characterize SMD, including psychiatric comorbidity, neurocognitive functioning, and a potential EEG bio-signature. Its pharmacotherapy component was described as preliminary, with feasibility of recruitment and enrollment among its aims. Those broader aims should be distinguished from the randomized treatment comparison: they concern characterization and feasibility as well as symptom measurement. The posted primary result does not provide the numerical information needed to judge the size or precision of the randomized contrast.

3. Trial Design

The registry lists this as a phase 2, randomized, quadruple-masked, parallel-group study sponsored by the University of California, Los Angeles. The record gives a start of 2013-01, primary completion of 2016-06, and status of completed. Enrollment is listed as 34. These record-level details describe the study, but they do not establish how many participants contributed to each outcome analysis.

The treatment sequence began with open-label lisdexamfetamine titration from baseline through the end of study week 4. The arm descriptions say participants were then randomized to adjunctive fluoxetine or adjunctive placebo. The brief summary describes an additional 8 weeks of blinded treatment in combination with optimized lisdexamfetamine. The primary outcome timeframe is baseline through week 12. These stages matter when interpreting group comparisons: the randomized contrast concerns the adjunctive treatments after the initial titration, rather than a comparison of lisdexamfetamine with no lisdexamfetamine.

The brief summary lists planned randomization groups of fluoxetine (N=25) and placebo (N=25), while the record lists overall enrollment of 34 and outcome-group counts that vary by measure. The record does not explain the relationship between those planned group counts and enrollment, and no reconciliation should be inferred. The primary outcome description notes that some participants discontinued as the trial progressed. Reasons for discontinuation, timing, and treatment adherence are not reported in the registry record.

The record identifies lisdexamfetamine, fluoxetine, and placebo as interventions. Details of the randomization method, allocation concealment, masking procedures, titration rules, and protocol deviations are not reported in the registry record. The listed design labels establish the broad study structure, not the operational details needed to assess how each procedure was implemented.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: At completion of open lisdexamfetamine, participants who achieved Clinical Global Impression Severity (CGI-S) SMD score \< 4 were deemed sufficiently improved, and not randomized to adjunctive treatment. N=4 participants were sufficiently improved and completed study participation at study week 4, prior to randomization

Open Lisdexamfetamine Titration

Reasons for not completing this period:

Double Blind Adjunctive Treatment

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Compares groups lisdexamfetamine plus fluoxetine vs. lisdexamfetamine plus placebo over 12 week trial. Some participants discontinued as trial progressed.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: See Participant Flow descriptions.

6. Primary Endpoint

The registry lists the primary outcome as Clinical Global Impression-Severity-Severe Mood Dysregulation, measured over Baseline through week 12..

The primary endpoint is the Clinical Global Impression-Severity-Severe Mood Dysregulation measure. It is described as a dimensional clinician rating of overall impairment related to SMD, modified by the National Institute of Mental Health to assess domains relevant to SMD. Its scale runs from a minimum score of 1 to a maximum score of 7, with higher scores indicating greater impairment. The stated unit is units on a scale.

A clinician-rated severity measure can provide a structured way to represent overall impairment rather than focusing on a single symptom. A continuous score can also retain distinctions across the scale, which may be useful for comparing group averages. These are general features of continuous clinical outcomes; they do not establish the validity or reliability of this particular modified measure in this trial. Information on validation, rating procedures, and assessor training is not reported in the registry record.

The record specifies least-squares means with standard errors as the summary format and identifies the timeframe as baseline through week 12. The stated population comparison is lisdexamfetamine plus fluoxetine versus lisdexamfetamine plus placebo, with some participants discontinuing during the trial. However, the registry record does not report a single primary-outcome result reduced to one comparison. It therefore does not give the numerical group estimates, their standard errors, or a numerical estimate of the between-group effect. Without those values, the direction, size, and precision of the primary comparison cannot be described.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The design is described as randomized, quadruple-masked, and parallel. In general, randomization is intended to make treatment assignment independent of participant characteristics, on average, while masking is intended to limit the influence of treatment knowledge on care, assessment, or reporting. A parallel design compares groups assigned to different treatments over the study period. These general purposes do not verify how the procedures worked in practice. The randomization sequence, allocation concealment, identity of masked parties, and masking checks are not reported in the registry record.

What does the primary summary measure?

The registry specifies least-squares means and standard errors for the continuous primary endpoint. In general, a least-squares mean is a model-based estimate of a group mean, often adjusted for terms in the statistical model. A standard error describes the estimated sampling uncertainty in an estimate; it is not the same quantity as the spread of individual participant scores. The registry record does not describe the model terms, covariance structure, or estimation procedure, and it provides no numerical least-squares means or standard errors for a single primary comparison. The model cannot therefore be reconstructed or independently evaluated from the reported information.

In general, a confidence interval combines an estimate and its uncertainty to show a range of values compatible with the data under the method used. A p-value addresses compatibility of the data with a specified null hypothesis under model assumptions; it does not give the probability that a treatment is effective. Neither a numerical confidence interval nor a single primary-comparison p-value is reported in the registry record. These general concepts explain how such statistics would be read, but they cannot fill in absent trial estimates.

How should the sequence affect interpretation?

The protocol description distinguishes open titration from randomized adjunctive treatment. The first stage involved open-label lisdexamfetamine through study week 4; the following stage randomized participants to fluoxetine or placebo alongside optimized lisdexamfetamine. Because the initial stage was open-label and shared before the randomized comparison, its changes should not be interpreted as a randomized drug-versus-placebo effect. The trial's intended randomized contrast is between the adjunctive groups. Detailed rules for selecting the optimal dose and the analysis of the titration stage are not reported in the registry record.

The primary outcome spans baseline through week 12, while the randomized adjunctive phase begins at the end of study week 4. In general, longitudinal clinical measurements can be analyzed using methods that account for repeated observations within the same participant. Such methods require choices about time, treatment, baseline values, and within-participant correlation. The registry record does not identify those model choices or show time-specific estimates. Its note that the primary outcome has several categories or time points and was not reduced to one comparison makes a single overall contrast unavailable in the posted result.

What can the planning assumptions tell us?

The record describes sample-size illustrations based on the observed effect, with a two-sided significance level of 0.05, equal allocation between arms, and a normal approximation. It says the effect to detect is a stated fraction of the observed effect. Such calculations are planning illustrations, not observed power and not proof that an analysis was adequately powered. Their interpretation depends on the effect estimate and other assumptions used. The numerical illustrations and the observed effect needed to evaluate them are not reported in the registry record, so no sample-size estimate can be assessed.

In general, planning calculations translate a hypothesized effect and variability into a prospective estimate of the number of participants needed under specified assumptions. They do not show the probability that a completed study found a true effect, and they cannot repair uncertainty from missing outcomes or analysis choices. The registry's stated assumptions are useful context, but the absence of numerical illustration results and primary outcome estimates limits what can be concluded from them.

Why does over-dispersion matter in general?

For count outcomes, over-dispersion means that observed variability exceeds what a simple count model assumes. If that feature is ignored, standard errors may be too small and uncertainty may be understated. This is a general statistical issue, not a reported feature of this trial's primary endpoint. The primary outcome is described as a continuous scale, and the registry does not report a count-model analysis for it. No claim about over-dispersion in these data is warranted.

Finally, a recalculation from posted summary statistics would be a simple unadjusted check, not a replacement for the sponsor's own analysis. The primary endpoint does not have the single comparison or numerical summaries required for such a recalculation in the registry record. Therefore no recalculated treatment effect, standard error, confidence interval, or p-value is available to compare with the sponsor's analysis.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 17 outcome measures and 32 analyses. It also names secondary measures, including the ADHD-IV Rating Scale, Conners Parent Global Index, Conners Global Index Emotional Lability Subscale - Parent Report, Conners Global Index Restless-Impulsive Subscale Parent Report, Conners Teacher Global Index, Affective Reactivity Index - Parent Report, Revised Modified Overt Aggression Scale - Total Score, and Clinical Global Impression - Improvement. Examining multiple outcomes, time points, or analyses can raise a multiplicity issue: in general, more statistical tests create more opportunities for apparently notable findings by chance. The registry record does not report a multiplicity adjustment, a prespecified testing hierarchy, or which analyses were primary versus exploratory beyond its designation of the primary outcome.

The record states that the primary outcome has several categories or time points and was not reduced to one comparison. This leaves the principal numerical contrast unspecified in the posted result. Details on endpoint selection, choice of time point, and handling of multiple comparisons are not reported in the registry record. Without them, the multiplicity approach cannot be evaluated.

Missing-data information is also limited. The primary outcome description says some participants discontinued as the trial progressed, but reasons, timing, group-specific outcome availability, and missing-data methods are not reported in the registry record. The record does not state the primary analysis population, whether participants were analyzed according to randomized assignment, or how post-discontinuation measurements were handled. These omissions matter because analysis of incomplete repeated measures depends on assumptions about the missingness process and the chosen model. No specific assumption or method should be inferred from the listed least-squares mean summary.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The registry reports serious adverse events, other adverse events, and deaths separately for fluoxetine, placebo, and open lisdexamfetamine. For fluoxetine, the serious-event count is 0 among 12 at risk, the other-event count is 8 among 12 at risk, and deaths are 0. For placebo, the serious-event count is 0 among 14 at risk, the other-event count is 10 among 14 at risk, and deaths are 0. For open lisdexamfetamine, the serious-event count is 0 among 34 at risk, the other-event count is 30 among 34 at risk, and deaths are 0.

These are the registry's counts and denominators for the listed groups; they should not be added together to infer unique participants or a combined safety rate. The open lisdexamfetamine group represents the initial open-label stage, while fluoxetine and placebo refer to the adjunctive groups. The record does not specify the adverse-event observation window, event definitions beyond the serious/other categories, severity grading, attribution to treatment, or whether an individual could contribute to more than one event category. The figures therefore describe reported counts, not causal effects. Serious adverse event terms are not listed, and the record reports no deaths in these groups.

12. What the Result Does, and Does Not, Mean

This record establishes that a randomized phase 2 study was conducted to characterize SMD and examine sequential pharmacotherapy. It describes open-label lisdexamfetamine titration followed by randomized adjunctive fluoxetine or placebo, and identifies a clinician-rated SMD impairment measure as the primary outcome. Those design details clarify the question the trial intended to address, but they do not reveal the magnitude or precision of the primary comparison.

The registry's primary outcome note says the outcome has several categories or time points and was not reduced to one comparison. No numerical least-squares mean, standard error, between-group estimate, confidence interval, or single primary-comparison p-value is reported in the record. As a result, the posted information cannot establish whether the randomized groups differed on the primary measure, how large any difference was, or how uncertain an estimate might be. The score's direction—higher values mean greater impairment—does not replace those results.

The safety figures report zero serious adverse events and zero deaths in each listed group, alongside counts for other adverse events. These registry counts are descriptive and do not establish that an intervention caused or prevented an event. The record does not provide the detail needed to assess event timing, attribution, or comparative risk.

Nor can the enrollment figure alone establish the size of the primary analysis or the completeness of follow-up. Some participants discontinued, but the reasons and missing-data handling are not reported in the registry record. The listed trial aims include feasibility and characterization, and the study is identified as phase 2; its design and reporting should be interpreted within that context. Overall, the record describes the study question and selected safety counts, but it does not provide the numerical primary result required to draw a conclusion about the randomized treatment contrast.

13. Why This Trial Matters Statistically

This trial is statistically notable for its sequential structure. Participants first underwent open-label lisdexamfetamine titration and then entered a randomized comparison of adjunctive fluoxetine versus placebo. That distinction defines the estimand—the treatment contrast the analysis is intended to estimate. The randomized comparison is not a test of lisdexamfetamine against placebo, and changes during the open stage cannot by themselves establish an effect of the randomized adjunctive treatment.

The endpoint is a continuous clinician-rated impairment score, and the registry identifies least-squares means with standard errors as its summary approach. These choices make the model and its assumptions relevant to interpretation. A complete report would ordinarily allow readers to connect the estimated group contrast to its uncertainty and to understand which time points and analysis population contributed. The registry record does not supply those details or reduce the primary outcome to a single comparison.

The record also lists multiple outcome measures and analyses, while reporting that some participants discontinued. Together, multiplicity and incomplete outcome availability make prespecification, model choice, missing-data handling, and transparent reporting especially important. The registry does not report enough detail to assess those decisions. The stated planning assumptions may be useful context, but the numerical planning illustrations are absent, and planning calculations cannot substitute for observed estimates and uncertainty.

These points matter because statistical interpretation depends on more than the study label or outcome definition. A randomized design establishes the intended comparison, while clear estimates and analysis details are needed to judge what the data show and how precisely. In this record, the design is described more fully than the primary numerical result. That gap limits statistical evaluation without implying any particular treatment effect.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific limitations arise from the registry information. The primary outcome is described over baseline through week 12, but its reported result is not reduced to a single comparison because it has several categories or time points. The record therefore does not provide a numerical summary of the primary randomized contrast. The model underlying the least-squares means, its covariates, and its handling of repeated measurements are not reported in the registry record.

Some participants discontinued as the trial progressed, but the record does not state why, when, or how discontinuation affected outcome availability. The primary analysis population and missing-data approach are not reported. The counts in the safety groups do not supply these missing primary-outcome details. The planned group sizes in the brief summary and the listed enrollment are both recorded, but the registry does not explain their relationship; they should not be treated as interchangeable analysis counts.

The study includes a broad set of secondary measures and analyses. A prespecified multiplicity plan and distinctions among confirmatory and exploratory analyses are not reported. The record also does not provide detailed eligibility criteria, participant characteristics, adherence, dose distribution, or information about how masking and randomization were implemented. These omissions limit assessment of applicability and study conduct.

Finally, safety reporting gives group counts but not adverse-event observation windows, event attribution, or event-level descriptions beyond the serious-event terms being absent. The listed counts are therefore descriptive. These limitations concern the detail available in the registry record; they do not determine what a fuller clinical study report might contain.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation — NCT01714310.
• Registry record last updated 2018-02-26; status last verified 2018-01.
• Results first posted 2018-02-26.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT01714310, Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation, is listed as a completed phase 2 randomized, quadruple-masked, parallel study sponsored by the University of California, Los Angeles. The registry gives a start of 2013-01, primary completion of 2016-06, and enrollment of 34.

The study description centers on open-label lisdexamfetamine titration through study week 4, followed by randomization to adjunctive fluoxetine or placebo. The primary outcome is a clinician-rated SMD impairment score over baseline through week 12, with higher scores indicating greater impairment. The record lists least-squares means and standard errors but does not report a single numerical primary comparison.

Safety reporting lists group counts for serious and other adverse events and deaths. Some participants discontinued, but the record does not give reasons or primary-outcome missing-data methods. The stated aims include characterization of SMD and a preliminary evaluation of sequential pharmacotherapy feasibility.